Physiomics Secures Approval for Cancer Dosing Software Trial
Physiomics plc (AIM: PYC), a forward-thinking company engaged in mathematical modeling and data science focused on therapeutic development, has achieved a significant milestone by receiving regulatory and ethical approval for its groundbreaking project, PREDICT-ONC. This trial is set to assess the performance of the company’s innovative software that aims to optimize chemotherapy dosing for cancer patients, particularly focusing on the drug GCSF, which is utilized to address neutropenia, a frequent complication associated with chemotherapy treatments.
Understanding the PREDICT-ONC Study
The PREDICT-ONC study is auspiciously backed by Innovate UK and The Office for Life Sciences and is designed to enhance the capabilities of Physiomics' personalized dosing software. This innovative software was initially funded with £355,376 in grants, targeting its application in assisting healthcare professionals with the accurate dosing of docetaxel, a chemotherapy drug.
The Impact of GCSF in Chemotherapy
Following the completion of the PARTNER study in early 2023, the software demonstrated potential beyond its initial scope, particularly in solidifying dosing strategies for GCSF. This drug plays a crucial role in reducing the detrimental effects of chemotherapy on white blood cell counts, thus protecting patients from severe side effects.
Clinical Trial Insights
The clinical trial aims to enroll breast cancer patients currently receiving standard GCSF treatment at Blackpool Teaching Hospitals NHS Foundation Trust. This initiative is in collaboration with Beyond Blood Diagnostics Limited and seeks to gather valuable data that will enhance the software's predictive models, ultimately aiming to provide tailored treatment regimens for individual patients.
Looking Ahead: Recruitment and Timeline
Although the initiation of the trial has experienced a setback from its initially anticipated start in the summer of 2024, Dr. Peter Sargent, the CEO of Physiomics, is optimistic about commencing recruitment swiftly. He reassures stakeholders that despite the delay, it is expected to have little to no effect on the overall project's completion timeline, which is projected between October and December 2025.
Collaborative Efforts in Cancer Treatment
Physiomics, together with its partners, is gearing up to begin the process of data collection from the trial. The insights gleaned from this research are expected to propel advancements in their personalized dosing software, ultimately contributing to better treatment outcomes for cancer patients. This step is not only pivotal for Physiomics but also promises to raise the standard of care in oncology.
Significance of Predictive Dosing Software
This new software embodies a significant leap in addressing the complexities of chemotherapy dosing. By leveraging mathematical modeling, Physiomics aims to personalize treatment in a way that is safe, effective, and responsive to each patient's unique needs.
Frequently Asked Questions
What is the PREDICT-ONC trial?
The PREDICT-ONC trial is a clinical study aimed at evaluating software developed by Physiomics to optimize cancer chemotherapy dosing, particularly focusing on the drug GCSF.
How does GCSF relate to chemotherapy?
GCSF is used to reduce the incidence of neutropenia, a common side effect of chemotherapy that can lead to severe complications for patients undergoing treatment.
What are the expected outcomes of the trial?
The trial aims to gather data that will improve the predictive capabilities of the personalized dosing software, ultimately enhancing treatment outcomes for cancer patients.
Who is funding the PREDICT-ONC study?
The study is funded by Innovate UK and The Office for Life Sciences, reflecting significant support for innovative healthcare solutions.
What has been the timeline for the trial's initiation?
Although the trial's start has been delayed, recruitment is expected to begin shortly, with project completion aimed for between October and December 2025.
